

20. The recombinant CHV according to claim 17 further comprising a strong eukaryotic promoter; wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter.

21. The recombinant CHV according to claim 20 wherein the strong eukaryotic promoter comprises a CMV immediate-early promoter.

22. The recombinant CHV of claim 21 wherein the CMV immediate-early promoter comprises a murine or human CMV immediate-early promoter.

23. The recombinant CHV according to claim 17 comprising at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter.

24. The recombinant CHV according to claim 23 wherein the eukaryotic promoters are CMV immediate-early promoters of different animal origin.

25. The recombinant CHV according to claim 23 comprising a first heterologous nucleotide sequence operably linked to a first promoter and a second heterologous nucleotide sequence operably linked to a second promoter; wherein, the first promoter comprises a CMV immediate-early promoter, and, the first and second promoters are arranged so that their 5' ends are adjacent.

26. The recombinant CHV according to claim 17 further comprising at least one heterologous nucleotide sequence encoding an immunomodulatory polypeptide.

27. The recombinant CHV according to claim 26 wherein the heterologous nucleotide sequence comprises a nucleotide sequence selected from the group consisting of nucleotide sequences encoding cytokines.

28. The recombinant CHV according to claim 17 wherein the heterologous nucleotide sequence comprises an expression cassette comprising from 5' to 3', a promoter, two or more coding regions separated in pairs by an internal ribosome entry site (IRES), and a polyadenylation signal.

29. The recombinant CHV of claim 17 comprising and expressing at least one heterologous nucleotide sequence encoding the canine distemper virus HA antigen

30. The recombinant CHV of claim 17 comprising and expressing at least one heterologous nucleotide sequence encoding the canine distemper virus F antigen.

31. The recombinant CHV of claim 17 comprising and expressing at least one heterologous nucleotide sequence encoding the rabies virus G antigen.

32. The recombinant CHV of claim 17 comprising and expressing at least one heterologous nucleotide sequence encoding the canine parvovirus VP2 antigen.

33. The recombinant CHV of claim 17 comprising and expressing at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 HA antigen.

34. The recombinant CHV of claim 17 comprising and expressing at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 F antigen.

35. The recombinant CHV of claim 17 comprising and expressing at least one heterologous nucleotide sequence encoding the *Borrelia burgdorferi* OspA antigen.

36. The recombinant CHV of claim 17 comprising and expressing at least one heterologous nucleotide sequence encoding the *Borrelia burgdorferi* OspB antigen.

37. The recombinant CHV according to claim 17 wherein the at least one heterologous nucleotide sequence is in the ORF3 (SEQ ID NO:4) site.

38. The recombinant CHV according to claim 17 wherein the at least one heterologous nucleotide sequence is in the ORF5 (SEQ ID NO:5) site.

39. The recombinant CHV according to claim 17 wherein the at least one heterologous nucleotide sequence is in the thymidine kinase gene site.

40. The recombinant CHV according to claim 17 wherein the at least one heterologous nucleotide sequence is in the intergenic region corresponding to genes coding for the large subunit and the small subunit site.

41. A vaccine or immunological composition comprising a recombinant CHV as claimed in any one of claims 17 to 40.

42. A multivalent vaccine or immunological composition comprising, as a mixture or to be admixed, at least a first recombinant CHV and a second recombinant CHV; wherein the first and second recombinant CHV are as claimed in any one of claims 17 to 40, and the heterologous nucleotide sequence in the first recombinant CHV is different than the heterologous nucleotide sequence in the second recombinant CHV.

43. A method for inducing an immunological response in a canine comprising administering to the canine a recombinant CHV as claimed in any one of claims 17 to 40.
44. A method for inducing an immunological response in a canine animal comprising administering to the canine a vaccine or immunological composition as claimed in claim 41.
45. A method for inducing an immunological response in a canine comprising administering to the canine a vaccine or immunological composition as claimed in claim 42.
46. The method of claim 43 wherein the administering comprises mucosally administering a dose comprising between 10^2 and 10^5 CCID₅₀ of the recombinant CHV.
47. The method of claim 44 wherein the administering comprises mucosally administering a dose comprising between 10^2 and 10^5 CCID₅₀ of the recombinant CHV.
48. The method of claim 45 wherein the administering comprises mucosally administering a dose comprising between 10^2 and 10^5 CCID₅₀ of the recombinant CHV.
49. A method for expressing a polypeptide selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, *Borrelia burgdorferi* OspA, *Borrelia burgdorferi* OspB, said method comprising contacting a suitable cell with a recombinant CHV as claimed in any one of claims 17 to 40.--

Kindly cancel claims 1-16, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.